Institution · Azevan Pharmaceuticals (United States)

Most cited papers from Azevan Pharmaceuticals (United States)

Azevan Pharmaceuticals (United States)

What are the most cited papers from Azevan Pharmaceuticals (United States)?

The most cited paper from Azevan Pharmaceuticals (United States) is "Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent" (Syed Faizan Mehdi, Suma Pusapati, Muhammad Saad Anwar et al., 2023), with 303 citations. Next come "Orally active vasopressin V1a receptor antagonist, SRX251, selectively blocks aggressive behavior" (105) and "Azetidinones as vasopressin V1a antagonists" (75).

Published FieldAccess

Showing 20 of 20 papers. Every paper is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent Syed Faizan Mehdi, Suma Pusapati, Muhammad Saad Anwar et al. · Frontiers in Immunology Open access	17 May 2023	303
2	Orally active vasopressin V1a receptor antagonist, SRX251, selectively blocks aggressive behavior Craig F. Ferris, Shi‐fang Lu, Tara L. Messenger et al. · Pharmacology Biochemistry and Behavior	Feb 2006	105
3	Azetidinones as vasopressin V1a antagonists Christophe D. Guillon, GARY A. KOPPEL, Michael Brownstein et al. · Bioorganic & Medicinal Chemistry Open access	26 Dec 2006	75
4	Neuroradiological Changes Following Single or Repetitive Mild TBI Praveen P. Kulkarni, Thomas R. Morrison, Xuezhu Cai et al. · Frontiers in Systems Neuroscience Open access	2 Aug 2019	63
5	A novel V1a receptor antagonist blocks vasopressin-induced changes in the CNS response to emotional stimuli: an fMRI study Royce J. Lee, Emil F. Coccaro, Henk R. Cremers et al. · Frontiers in Systems Neuroscience Open access	2013	51
6	Endocrine and metabolic alterations in response to systemic inflammation and sepsis: a review article Syed Faizan Mehdi, M. Qureshi, Salman Pervaiz et al. · Molecular Medicine Open access	21 Jan 2025	49
7	Oxytocin and Related Peptide Hormones: Candidate Anti-Inflammatory Therapy in Early Stages of Sepsis Syed Faizan Mehdi, Suma Pusapati, Raja Ram Khenhrani et al. · Frontiers in Immunology Open access	29 Apr 2022	42
8	Vasopressin stimulates the proliferation and differentiation of red blood cell precursors and improves recovery from anemia Balázs Mayer et al. · Science Translational Medicine Open access	29 Nov 2017	40
9	The novel vasopressin receptor (V1aR) antagonist SRX246 reduces anxiety in an experimental model in humans: a randomized proof-of-concept study Tiffany R. Lago, Michael Brownstein, Emily Page et al. · Psychopharmacology Open access	10 May 2021	37
10	Pharmacokinetics and Metabolism of SRX246: A Potent and Selective Vasopressin 1a Antagonist Karine M. Fabio, Christophe D. Guillon, Shi‐fang Lu et al. · Journal of Pharmaceutical Sciences	7 Mar 2013	33
11	Safety and Tolerability of SRX246, a Vasopressin 1a Antagonist, in Irritable Huntington’s Disease Patients—A Randomized Phase 2 Clinical Trial Michael Brownstein et al. · Journal of Clinical Medicine Open access	16 Nov 2020	32
12	Synthesis and evaluation of potent and selective human V1a receptor antagonists as potential ligands for PET or SPECT imaging Karine M. Fabio, Christophe D. Guillon, Carl Jeffrey Lacey et al. · Bioorganic & Medicinal Chemistry Open access	20 Dec 2011	25
13	Evidence of early vasogenic edema following minor head impact that can be reduced with a vasopressin V1a receptor antagonist Praveen P. Kulkarni, Mansi R. Bhosle, Shi‐fang Lu et al. · Brain Research Bulletin Open access	11 Oct 2020	19
14	Treating head injury using a novel vasopressin 1a receptor antagonist Thomas R. Morrison, Praveen P. Kulkarni, Xuezhu Cai et al. · Neuroscience Letters	20 Oct 2019	16
15	The Vasopressin 1a Receptor Antagonist SRX246 Reduces Aggressive Behavior in Huntington’s Disease Hilda T. Maibach, Michael Brownstein, Steven M. Hersch et al. · Journal of Personalized Medicine Open access	22 Sep 2022	11
16	A proof-of-concept randomized crossover clinical trial of a first-in-class vasopressin 1a receptor antagonist for PTSD: Design, methods, and recruitment JoAnn Difede, Andrew A. McAleavey, Mariel Emrich et al. · Contemporary Clinical Trials Communications Open access	17 Mar 2023	6
17	Effects of SRX246, a Vasopressin 1a Receptor (V1a) Antagonist, on an Experimental Model of Phasic and Sustained Threat in Humans Tiffany R. Lago, Michael Brownstein, Emily M. Beydler et al. · Biological Psychiatry	May 2020	3
18	The utility of the irritability scale in Huntington's disease patients with evidence of irritability or aggression Joyce En‐Hua Wang, Neal G. Simon, Michael Brownstein et al. · Parkinsonism & Related Disorders	30 Mar 2024	2
19	Vasopressin 1a Receptor Antagonists for Pathological Aggression in Neurodegenerative and Other CNS Diseases Neal G. Simon, Michael Brownstein, Karen E. Anderson et al. · Biomedicines Open access	14 Apr 2026	0
20	NLRC4 inflammasomes: ‘their appearance and their work was a wheel in the middle of a wheel’ Michael Brownstein · Oral Diseases	8 Dec 2015	0

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.